49.35
price down icon0.26%   -0.13
after-market Handel nachbörslich: 49.35
loading
Schlusskurs vom Vortag:
$49.48
Offen:
$49.43
24-Stunden-Volumen:
2.92M
Relative Volume:
1.35
Marktkapitalisierung:
$121.16B
Einnahmen:
$48.62B
Nettoeinkommen (Verlust:
$6.80B
KGV:
17.60
EPS:
2.8038
Netto-Cashflow:
$7.62B
1W Leistung:
+1.23%
1M Leistung:
+3.13%
6M Leistung:
-5.37%
1J Leistung:
-5.26%
1-Tages-Spanne:
Value
$49.10
$49.70
1-Wochen-Bereich:
Value
$49.10
$50.49
52-Wochen-Spanne:
Value
$45.80
$60.12

Sanofi Adr Stock (SNY) Company Profile

Name
Firmenname
Sanofi Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
82,878
Name
Twitter
@sanofi
Name
Nächster Verdiensttermin
2024-10-25
Name
Neueste SEC-Einreichungen
Name
SNY's Discussions on Twitter

Vergleichen Sie SNY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - General icon
SNY
Sanofi Adr
49.35 120.44B 48.62B 6.80B 7.62B 2.8038
Drug Manufacturers - General icon
LLY
Lilly Eli Co
762.95 725.47B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
168.11 400.31B 90.63B 22.66B 16.40B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
191.22 333.00B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
117.22 224.91B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
MRK
Merck Co Inc
82.63 211.08B 63.92B 17.43B 17.04B 6.87

Sanofi Adr Stock (SNY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-15 Eingeleitet Exane BNP Paribas Outperform
2025-03-21 Eingeleitet Goldman Neutral
2025-01-30 Hochstufung Deutsche Bank Sell → Hold
2024-07-26 Bestätigt Argus Buy
2024-01-23 Eingeleitet Morgan Stanley Equal-Weight
2024-01-16 Fortgesetzt UBS Buy
2023-12-05 Herabstufung JP Morgan Overweight → Neutral
2023-10-30 Herabstufung Stifel Buy → Hold
2023-09-06 Hochstufung Berenberg Hold → Buy
2023-07-14 Eingeleitet HSBC Securities Buy
2023-04-28 Herabstufung Deutsche Bank Hold → Sell
2023-03-27 Hochstufung Barclays Equal Weight → Overweight
2022-12-13 Fortgesetzt Morgan Stanley Overweight
2022-08-12 Hochstufung Deutsche Bank Sell → Hold
2022-08-09 Herabstufung UBS Buy → Neutral
2022-05-23 Eingeleitet SVB Leerink Outperform
2021-09-27 Hochstufung SVB Leerink Mkt Perform → Outperform
2021-01-15 Eingeleitet Deutsche Bank Sell
2020-09-29 Eingeleitet Berenberg Hold
2020-03-17 Hochstufung Barclays Underweight → Equal Weight
2020-03-11 Hochstufung Goldman Neutral → Buy
2020-02-11 Eingeleitet SVB Leerink Mkt Perform
2020-01-06 Hochstufung JP Morgan Neutral → Overweight
2019-09-23 Hochstufung Guggenheim Neutral → Buy
2019-09-20 Hochstufung Morgan Stanley Equal-Weight → Overweight
2019-09-03 Eingeleitet Bernstein Outperform
2019-08-14 Hochstufung UBS Neutral → Buy
2018-12-11 Hochstufung Jefferies Hold → Buy
2018-11-01 Hochstufung Barclays Underweight → Equal Weight
2018-10-09 Eingeleitet Guggenheim Neutral
2018-09-10 Hochstufung BofA/Merrill Neutral → Buy
2018-08-10 Hochstufung Citigroup Neutral → Buy
2018-03-23 Hochstufung Liberum Hold → Buy
2018-01-23 Herabstufung Barclays Equal Weight → Underweight
2017-12-06 Herabstufung BofA/Merrill Buy → Neutral
2017-12-01 Herabstufung Morgan Stanley Overweight → Underweight
2017-11-15 Hochstufung Barclays Underweight → Equal Weight
2017-08-30 Hochstufung HSBC Securities Reduce → Hold
Alle ansehen

Sanofi Adr Aktie (SNY) Neueste Nachrichten

pulisher
Jul 29, 2025

Hematologist Dissatisfaction with Current Warm Autoimmune Hemolytic Anemia (w-AIHA) Treatment Spurs Interest in Late-Stage Pipeline, According to Spherix Global Insights - GlobeNewswire Inc.

Jul 29, 2025
pulisher
Jul 27, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SanofiSNY - cnhinews.com

Jul 27, 2025
pulisher
Jul 24, 2025

Sanofi: Reassessing Our Moat Rating for This Leader in Immunology, Vaccines, and Rare Diseases - Morningstar

Jul 24, 2025
pulisher
Jul 24, 2025

Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar

Jul 24, 2025
pulisher
Jul 22, 2025

BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study - Ariva

Jul 22, 2025
pulisher
Jul 21, 2025

AstraZeneca pledges $50 bln investment in US as pharma tariffs loom By Investing.com - Investing.com

Jul 21, 2025
pulisher
Jul 01, 2025

Adagene stock gains as Sanofi expands agreement (ADAG:NASDAQ) - Seeking Alpha

Jul 01, 2025
pulisher
Jun 13, 2025

SNY’s 2023 Market Dance: Up 3.92% – Time to Invest? - investchronicle.com

Jun 13, 2025
pulisher
Jun 09, 2025

Sanofi: Information concerning the total number of voting rights and shares - GlobeNewswire Inc.

Jun 09, 2025
pulisher
Jun 02, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Jun 02, 2025
pulisher
Jun 02, 2025

France’s Sanofi to buy U.S. biopharma group Blueprint for up to $9.5-billion - The Globe and Mail

Jun 02, 2025
pulisher
Jun 02, 2025

Sanofi doubles down on immunology with $9.1bn Blueprint deal - Proactive financial news

Jun 02, 2025
pulisher
May 31, 2025

European ADR Index Slips As Pharma Stocks Buck The Trend - Finimize

May 31, 2025
pulisher
May 30, 2025

Regeneron and Sanofi: Disappointing Top-Line Results for Itepekimab From Two Phase 3 Trials - Morningstar

May 30, 2025
pulisher
May 30, 2025

Regeneron Pharmaceuticals Crashes 19% On A Surprise Sanofi-Tied Failure - Investor's Business Daily

May 30, 2025
pulisher
May 30, 2025

Market movers: Canopy Growth, Zscaler, Regeneron... - Proactive financial news

May 30, 2025
pulisher
May 30, 2025

Regeneron shares plunge after mixed COPD drug trial results - Proactive financial news

May 30, 2025
pulisher
May 29, 2025

Penicillin Market Research Report 2025 - GlobeNewswire Inc.

May 29, 2025
pulisher
May 29, 2025

Sanofi: New Anthem from Girl Band Raises Awareness of Type 1 Diabetes After Research Highlights Silent Struggle - Ariva

May 29, 2025
pulisher
May 26, 2025

Prurigo Nodularis Market - GlobeNewswire Inc.

May 26, 2025
pulisher
May 23, 2025

8MM Bronchiectasis Market Opportunity Assessment and Forecasts, 2033 - GlobeNewswire Inc.

May 23, 2025
pulisher
May 22, 2025

Dollar Stock Biotech Triples On $470 Million Sanofi Takeover - Investor's Business Daily

May 22, 2025
pulisher
May 08, 2025

Metric Deep Dive: Understanding Sanofi ADR (SNY) Through its Ratios - DWinneX

May 08, 2025
pulisher
May 02, 2025

iRhythm Technologies Inc (IRTC) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com

May 02, 2025
pulisher
May 02, 2025

WLK’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com

May 02, 2025
pulisher
May 02, 2025

BIDU’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

May 02, 2025
pulisher
May 02, 2025

A Tale of Resilience: Sanofi ADR Amid Stock Market Turbulence - investchronicle.com

May 02, 2025
pulisher
May 02, 2025

Company’s Banking Stock: Dissecting a 40.08% Quarterly Revenue Decline Amid Growth - investchronicle.com

May 02, 2025
pulisher
May 02, 2025

Trip.com Group Ltd ADR (TCOM) Stock: A Year of Stock Market Ups and Downs - investchronicle.com

May 02, 2025
pulisher
May 02, 2025

CYTK’s 2023 Market Dance: Down -21.41% – Time to Invest? - investchronicle.com

May 02, 2025

Finanzdaten der Sanofi Adr-Aktie (SNY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_general PFE
$24.30
price down icon 0.04%
$114.23
price up icon 1.06%
$303.56
price up icon 0.75%
drug_manufacturers_general NVO
$53.94
price down icon 21.83%
drug_manufacturers_general MRK
$82.63
price down icon 1.70%
Kapitalisierung:     |  Volumen (24h):